The DOI matches its Crossref record; 330 of the 334 references it cites were found in a registry or an index.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Open accessAbstract
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For this patient population, there is currently no efficacious treatment option available [4].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The current standard of care for GBM includes surgical resection and post-surgery radiotherapy with or without temozolomide (TMZ) chemotherapy [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Despite standard of care treatment, GBM recurrence is inevitable and there is no agreed salvage therapy post-recurrence [4, 5].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationThe 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella‐Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,703
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
Self-citationComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,517
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Research works printed but not linked: 3
- World Health Organization., 2016, Histological Classification of Tumors of The Central Nervous System
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), 2019, Central Nervus System Cancers
- Chang, 2019, Neoplasms of the central nervous system., 1568
Cited by
Sorted by citations
Items 701–800 of 1,000
Corridore, S., Verreault, M., Martin, H., Delobel, T., Carrère, C., Idbaïh, A., & Ballesta, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70027 · Cited by 4
“However, in the absence of therapeutic alternatives, TMZ is the standard of care in first line for all GBM patients irrespective of MGMT promoter methylation status or MMR gene expression (Wen et al., 2020).”
Bertolini, G., Trombini, T., Zenesini, C., Mazza, S., Dascola, I., Pavarani, A., Michiara, M., Ceccon, G., Peluso, A., Specchia, F. M. C., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05096-9 · Cited by 4
“Glioblastoma (GBM) represents the most common primary malignant tumor of the brain and even with the best standard-of-care the overall survival (OS) is approximately 15 months [1, 2].”
InfluentialSchweiger, M. W., & Tannous, B. A. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000035 · Cited by 4
Gossypol Treatment Restores Insufficient Apoptotic Function of DFF40/CAD in Human Glioblastoma Cells
Martínez‐Escardó, L., Alemany, M., Sánchez‐Osuna, M., Sánchez‐Chardi, A., Roig-Martínez, M., Suárez–García, S., Ruiz‐Molina, D., Vidal, N., Plans, G., Majós, C., et al. (2021) · Cancers · doi:10.3390/cancers13215579 · Cited by 4
“Almost all GBM-affected patients suffer from recurrences even after complete gross resection and radiochemotherapy [1].”
Rammohan, N., Ho, A., Saxena, M. V., Bajaj, A., Kruser, T., Horbinski, C., Korutz, A., Tate, M., & Sachdev, S. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04018-3 · Cited by 4
“One possibility is that MGMTmethylated patients have significantly stronger benefit from an alkylating agent like TMZ, which may nullify any negative prognostication based on TA-WMS.”
BackgroundInfluentialSelf-citationMazzaschi, G., Olivari, A., Pavarani, A., Lagrasta, C. A. M., Frati, C., Madeddu, D., Lorusso, B., Dallasta, S., Tommasi, C., Musolino, A., et al. (2022) · Cancers · doi:10.3390/cancers14133249 · Cited by 4
“The growth characteristics and spread dynamic coupled with treatment resistance make glioblastoma (GB) among the deadliest of all cancers, with a median survival rate of 14–16 months despite intensive regimens including surgery, radiotherapy, and chemotherapy [1,2].”
BackgroundDemogeot, N., Salleron, J., Rech, F., Taillandier, L., Royer, P., & Vogin, G. (2022) · Radiation Oncology · doi:10.1186/s13014-022-02169-1 · Cited by 4
“Forty-five (76%) patients were reirradiated on the first recurrence of GBM, 10 (17%) on the second recurrence [4, 6], 3 (5%) on the third recurrence (systemic therapy) and 1 (2%) on the fourth recurrence (systemic therapy).”
BackgroundSilginer, M., Papa, E., Szabó, E., Vasella, F., Pruschy, M. N., Stroh, C., Roth, P., Weiß, T., & Weller, M. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01527-8 · Cited by 4
“Introduction Glioblastoma is an intrinsic malignant brain tumor probably derived from neuroglial progenitor cells characterized morphologically by invasive growth, focal necrosis and angiogenesis and on the molecular level by frequent genetic alterations involving the receptor tyrosine kinase (RTK)/RAS/phosphatidylino…”
BackgroundSelf-citationLiu, K., Dallas, J., Wenger, T. A., Richards, H. W., Ding, L., Chow, F. E., Zada, G., Mack, W. J., & Attenello, F. J. (2023) · Surgical Neurology International · doi:10.25259/sni_440_2023 · Cited by 4
“[13,18,27] Resection of the tumor not only reduces the tumor burden but also relieves the mass effect on the brain to preserve neurological function.[35] However, resection is not curative as malignant brain tumors have high reoccurrence rates.”
BackgroundWeller, J. M., Zeyen, T., Schäfer, N., Schaub, C., Potthoff, A., Steinbach, J. P., Hau, P., Seidel, C., Goldbrunner, R., Tabatabai, G., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04470-9 · Cited by 4
“Glioblastoma is the most common and aggressive adult primary brain tumor [1].”
Yang, X., Wang, J., & Liu, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-45129-9 · Cited by 4
Liang, C.-C., Zhai, B., Deng, W., Niu, B., Ma, J., Yao, Y., Yang, L., Liu, Y., Liu, X., & Wang, P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130642 · Cited by 4
Zeitlberger, A. M., Putora, P. M., Höfer, S., Schucht, P., Migliorini, D., Hottinger, A. F., Roelcke, U., Laubli, H. P., Spina, P., Bozinov, O., et al. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04022-7 · Cited by 4
Self-citationGerritsen, J. K. W., Vincent, A. J. P. E., & Vleeschouwer, S. D. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa288 · Cited by 4
“applyparastyle "fig//caption/p[1]" parastyle "FigCapt" applyparastyle "fig" parastyle "Figure"”
BackgroundHurdling over the blood–brain barrier with exosome technology
Felker, J. T., & Agnihotri, S. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac214 · Cited by 4
Garcia, J. H., Akins, E. A., Jain, S., Wolf, K. J., Zhang, J. Y., Choudhary, N. R., Lad, M., Shukla, P. D., Gill, S. A., Carson, W., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.23.529575 · Cited by 4
Lecce, M., Rasile, F., Tanzilli, A., Gaviani, P., Carosi, M., Villani, V., Pace, A., Terrenato, I., Casini, B., Novello, M., et al. (2024) · Future Oncology · doi:10.1080/14796694.2024.2358743 · Cited by 3
Outcomes of awake surgery for recurrent glioblastoma: A single-institution retrospective analysis
Osawa, S., Kawauchi, D., Ohno, M., Miyakita, Y., Takahashi, M., Yanagisawa, S., Fujita, S., Tsuchiya, T., Matsumi, J., Sato, T., et al. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111113 · Cited by 3
Lazaridis, L., Mönninghoff, C., Bumes, E., Spille, D. C., Müther, M., Schulz, T., Heider, S., Agkatsev, S., Schmidt, T., Blau, T., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70689 · Cited by 3
An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma
Jackson, J. W., Hall, B. L., Sneiderman, C. T., Webb, A., Hancock, T. J., Vlasyuk, M., Bailey, L., Mo, X. M., Solomon, I. H., Ligon, K. L., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201030 · Cited by 3
Self-citationNeuropeptide adrenomedullin remodels stemness and macrophage dynamics in glioblastoma
Ali, H. A., Khan, F., Xuan, W., Liu, Y., Huang, Y., Whitfield, D., Pang, L., & Chen, P. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116342 · Cited by 3
Zeyen, T., Krause, I., Decker, A., Kroh, F., Regnery, S., Weller, J. M., Schaefer, N., Zidan, M., Potthoff, A., Schneider, M. B., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf261 · Cited by 3
Gallotti, A. L., Pecco, N., Pieri, V., Cominelli, M., Brugnara, G., Altabella, L., Pagano, I., Callea, M., Fodor, A., Gagliardi, F., et al. (2025) · European Radiology Experimental · doi:10.1186/s41747-025-00652-4 · Cited by 3
“Glioblastoma (GBM) is the most common and malignant primary brain tumor of adults [1, 2], with a very severe prognosis of 15 – 18 months [3, 4].”
Kee, H., Lee, H., Park, J., Jang, S., & Park, S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114408 · Cited by 3
Fontes, M., Garcez, D., Ruivo, J., Albuquerque, C., Viegas, C., da Cruz-Ribeiro, M., Lima, J. P., Mafra, M., Marques, J. B., & Fior, R. (2025) · Communications Medicine · doi:10.1038/s43856-025-01314-7 · Cited by 3
Silginer, M., Weller, M., Becher, B., Mastall, M., Weiß, T., Núñez, N. G., Kienzler, J. C., & Roth, P. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011824 · Cited by 3
Self-citationmiR-181d coordinates homologous recombination and anti-tumor immune responses in glioblastoma
Singh, G., Singh, S., Mohapatra, I., Hou, J., Ni, A., Barik, D., Zheng, H., Kim, S., Sharma, M., Lawler, S. E., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115077 · Cited by 3
“20,21 The current standard-of-care involves maximal safe resection, followed by treatment with concurrent temozolomide (TMZ) and ionizing radiation (IR), 22,23 both DNA-damaging agents.”
Pishavar, E., Shojaei-Ghahrizjani, F., Meehan, B., Tawil, N., Spinelli, C., Choi, D., Wong, F. C., Jalali, M., & Rak, J. W. (2026) · Journal of Extracellular Biology · doi:10.1002/jex2.70134 · Cited by 3
“Within GBM diagnosis different disease subgroups vary with respect to molecular make up and EGFR status (Wen et al. 2020 ; Neftel et al. 2019 ).”
Paolinelli, P. S., Azcona, T. S., Casto, F. B., Jungberg, E., Nuñez, N. T., Blettler, W., Pazos, J. S., Dell’Era, S., Lynch, C., Villaescusa, M., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1731276 · Cited by 3
“Glioblastoma, the most frequent glioma subtype, is associated with markedly poor survival (4, 5).”
Lee, J., Jeon, Y. S., Jang, J., Eum, H., Kim, M., Park, S. H., Park, C.-K., Choi, S. H., Ahn, S. S., & Choi, K. S. (2026) · Radiology Artificial Intelligence · doi:10.1148/ryai.250675 · Cited by 2
Tang, P., Zhao, J., & Tang, L. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.04.031 · Cited by 3
Redox rewiring in glioblastoma: the thioredoxin system as a precision therapeutic target
Espinoza, H., Gómez-Barrientos, A., López-Godoy, F., Tapia, P. J., & Puebla, M. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00857-3 · Cited by 3
Biomarkers for predicting immunotherapy response and resistance in glioblastoma
Kim, S., Abikenari, M. A., Bergsneider, B. H.-L., Kim, L. H., & Lim, M. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1823338 · Cited by 3
Self-citationIntracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
Zhang, Y., Chi, X., Feng, R., Xian, N., Huang, N., Sun, S., Zhao, X., Zhang, P., Liu, K., Ma, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04557-6 · Cited by 3
van Diest, E., Oldenmenger, W. H., Eland, M., & Taal, W. (2022) · Neuro-Oncology Practice · doi:10.1093/nop/npac033 · Cited by 3
Ermiş, E., Althaus, A., Blatti, M., Uysal, E., Leiser, D., Norouzi, S., Riggenbach, E., Hemmatazad, H., Ahmadli, U., & Wagner, F. (2023) · Cancers · doi:10.3390/cancers15061677 · Cited by 3
“Despite recent advances in understanding its biology and treatment options, including surgery, radiation therapy, systemic treatment (chemotherapy and targeted therapy), and tumor-treating fields, the prognosis remains very poor, with a 5-year survival rate of less than 10% [2].”
BackgroundTissue factor at the crossroads of coagulation and radiation response in glioblastoma
Mackman, N., Tawil, N., & Rak, J. W. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.10.018 · Cited by 3
Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma
Nabavizadeh, A., & Bagley, S. J. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3027 · Cited by 3
Exosomes as a Future Diagnostic Tool for Brain Disorders
Bhawale, R., Vasave, R., & Mehra, N. K. (2024) · Springer eBooks · doi:10.1007/978-981-99-8373-5_14 · Cited by 3
A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma
Pelaz, S. G., Flores-Hernández, R., Vujić, T., Schvartz, D., Álvarez-Vázquez, A., Ding, Y., García-Vicente, L., Belloso, A., Talaverón, R., Sánchez, J.-C., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.06.001 · Cited by 3
Network‐Based Transcriptome Analysis Reveals FAM3C as a Novel Potential Biomarker for Glioblastoma
Chagas, P. S., Chagas, H. I. S., Naeini, S. E., Bhandari, B., Gouron, J., Malta, T. M., Salles, É. L., Wang, L. P., Yu, J. C.-K., & Baban, B. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30612 · Cited by 4
“The GBM is typically characterized by high heterogeneity (both intertumoral and intratumoral), a critical frontier in understanding how the TME propels malignant progression and chemoresistance [1, 33].”
Li, P., Su, G., & Cui, Y. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01454-5 · Cited by 5
“Glioblastoma (GBM), a prevalent malignant tumor in the central nervous system, accounts for approximately 100,000 new diagnoses worldwide annually [1].”
BackgroundUram, Ł. S., Twardowska, M., Szymaszek, Ż., Misiorek, M., Łyskowski, A., Setkowicz, Z., Rauk, Z., & Wołowiec, S. (2024) · Molecules · doi:10.3390/molecules29184293 · Cited by 3
“Despite significant progress in surgical techniques and radio-and chemotherapy over the last decade, the prognosis for patients with GBM remains bleak, with a median survival of only 12–15 months [5] and a 5-year patient survival rate of 3% [6].”
BackgroundMaher, E. A., & Bachoo, R. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00047-9 · Cited by 3
The peritumoral brain zone in glioblastoma: a review of the pretreatment approach
Michalska, A., Bujko, M., Kwiatkowska-Miernik, A., Ziemba, K., Sklinda, K., Walecki, J. M., & Mruk, B. (2024) · Polish Journal of Radiology · doi:10.5114/pjr/192044 · Cited by 3
Trends in the immunotherapy for glioblastoma: A two-decade bibliometric analysis
Zhi Gao, L. O. N. G., Yi, Z., Yan, W., & Wang, H. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2466299 · Cited by 4
Mut, M., Zengin, H. Y., Azizova, A., Askun, C. S., Schiff, D., & Söylemezoğlu, F. (2025) · Brain Sciences · doi:10.3390/brainsci15050463 · Cited by 3
Self-citationEphrinA2 promotes glioma cell migration and invasion through EphA2 and FAK
Hirai, N., Tamai, S., Ichinose, T., Sabit, H., Saito, N., Iwabuchi, S., & Nakada, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03826-7 · Cited by 3
“Glioblastoma (GBM), a highly invasive primary brain tumor, has a poor prognosis with a median overall survival of 14–16 months and a 5-year survival rate of only approximately 10% despite surgical resection, chemotherapy, and radiation therapy [1, 2].”
Point/counterpoint: The role of re-resection in recurrent glioblastoma
Young, J. S., Berger, M. S., Lasocki, A., Suwala, A. K., Niyazi, M., Chang, S. M., Schnell, O., & Karschnia, P. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf127 · Cited by 3
Self-citationZhao, Y., Xu, Z., Liu, Y., Ye, M., Chen, R., Cao, Z., Zhou, H., & Zhou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1624142 · Cited by 3
Ferreira, C. C., Ferreira, M. Y., Cardoso, L. J. C., Scarramal, J. P. L., Nogueira, A., Wong, T., Bokil, S., Singh, F., Massimo, S., Albers, O., et al. (2025) · Journal of NeuroInterventional Surgery · doi:10.1136/jnis-2025-024057 · Cited by 3
Hakan, T., & Çelikoğlu, E. (2021) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_553_20 · Cited by 3
“Furthermore, MR spectroscopy (MRS) and positron emission tomography (PET) with 11C‐methionine (MET) (MET–PET) are very valuable imaging techniques for patients with any identifiable or challenging lesions.[16,17] Increased choline and reduced N‐acetylaspartate levels detected and revealed MET uptake in the lesion in M…”
BackgroundEllingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000543 · Cited by 3
Self-citationChen, J., Cen, B., Hu, F., Qiu, Y., Xiao, G.-M., Zhou, J., & Zhang, F. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i1.296 · Cited by 3
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials
Baldini, C., Younan, N., Álvarez, E. C., Ammari, S., Alentorn, A., Dumont, S., Frenel, J., Stefano, A. L. D., Louvel, G., Michot, J., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.017 · Cited by 3
Self-citationWee, C. W., Yoon, H. I., Lee, S.-W., & Lim, D. H. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac060 · Cited by 3
Грязов, А. А., Glavatskyi, O., Zemskova, O. V., Gryazov, A. B., Chuvashova, O. Y., Khmelnytskyi, H. V., Shuba, I. M., Владимировна, К. И., Shevelov, M. M., & Stuley, V. A. (2022) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.1(128).2022.57-73 · Cited by 3
Yin, L., Yao, Z., Wang, Y., & Mazuranic, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915862 · Cited by 3
Inmunopatología del Glioblastoma Multiforme y su importancia en el ámbito clínico
Rodríguez, M. P. T., Garcia, K. A. M., Baquero, C. A. C., & Cruz, A. D. P. I. (2022) · Revista Ciencias Biomédicas · doi:10.32997/rcb-2022-3738 · Cited by 3
Complement Components in Peripheral Blood from Adult Patients with IDH Wild-Type Glioblastoma
Förnvik, K., Liljedahl, E., Osther, K., Bengzon, J., Skattum, L., & Redebrandt, H. N. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.06.133 · Cited by 3
Ferré, A. E., Komaty, S., Hélaine, C., Anfray, C., Ghojavand, S., Coupey, J., Saulnier, R., Bernay, B., Chazalviel, L., Mintova, S., et al. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113524 · Cited by 3
The impact of intraoperative MRI on cranial surgical site infections—a single-center analysis
Joerger, A.-K., Laho, X., Kehl, V., Meyer, B., Krieg, S. M., & Ille, S. (2023) · Acta Neurochirurgica · doi:10.1007/s00701-023-05870-6 · Cited by 3
“For glioma as well as for intracranial metastases it has been shown that a gross total resection is associated with an improved outcome [4, 22, 24].”
BackgroundShirai, Y., Ueno, T., Kojima, S., Ikeuchi, H., Kitada, R., Koyama, T., Takahashi, F., Takahashi, K., Ichimura, K., Yoshida, A., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04563-z · Cited by 3
Prasetiyo, P. D., & Wahjoepramono, E. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154332 · Cited by 3
“A glioma is a very aggressive tumor that exhibits rapid growth and has a brief period of disease progression [1,2].”
BackgroundCost-effectiveness analysis of 11 pharmacotherapies for recurrent glioblastoma in the USA and China
Xu, Y., Xu, B., Guan, H., & Zhao, Z. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241264727 · Cited by 3
Ramírez, M. D. J. E., Коновалов, Н. А., Kaprovoy, S., Chmutin, G. E., Cerna, G. V., Nurmukhametov, R. M., Rosario, A. R., Yakovlevich, K. I., Lafuente, J., Molina, E. S., et al. (2024) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2403244 · Cited by 3
Snake venom bioprospecting as an approach to finding potential anti-glioblastoma molecules
Mera, J. O., Montoya‐Gómez, A., Lopes, D. S., & Jiménez–Charris, E. (2024) · The Journal of venomous animals and toxins including tropical diseases · doi:10.1590/1678-9199-jvatitd-2024-0015 · Cited by 3
“Unfortunately, some patients relapse early, while others around the first 10 to 12 months, but relapse invariably appears [7].”
BackgroundMethodInfluentialTumor treating induced fields: a new treatment option for patients with glioblastoma
Cai, Z., Yang, Z., Wang, Y., Li, Y., Zhao, H., Zhao, H., Yang, X., Wang, C., Meng, T., Xiao, T., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1413236 · Cited by 3
Traditional and advanced AI methods used in the area of neuro-oncology
Panda, S., Biswal, S. S., Rath, S. S., & Saxena, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18509-0.00008-6 · Cited by 4
Sansone, G., Lombardi, G., Maccari, M., Gaiola, M., Pini, L., Cerretti, G., Guerriero, A., Volpin, F., Denaro, L., Corbetta, M., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae415 · Cited by 3
BST2 and DIRAS3 Drive Immune Evasion and Tumor Progression in High-Grade Glioma
Liao, Z., Wu, S., Shi, Z., Chen, D., Chen, J., & Zhang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136205 · Cited by 3
Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma
Galanis, E., Wen, P. Y., de Groot, J., & Weller, M. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.08.007 · Cited by 3
Self-citationBasic premises: searching for new targets and strategies in diffuse gliomas
Sansone, G., Vivori, N., Vivori, C., Stefano, A. L. D., & Pïcca, A. (2022) · Clinical and Translational Imaging · doi:10.1007/s40336-022-00507-7 · Cited by 3
“It has been modelled that three main features are required to sustain GBM formation and progression: (a) initiation of tumour growth and proliferative advantage over neighbouring cells, (b) evasion of cellular senescence programs, and (c) replicative immortality [3, 44].”
BackgroundGlioblastoma in Patients With Multiple Sclerosis
Berkman, J. M., Nakhate, V., & Castro, L. N. G. (2022) · The Neurohospitalist · doi:10.1177/19418744221106003 · Cited by 4
“In our Discussion, we provide recommendations for distinguishing neoplastic from demyelinating lesions, review the evidence for demyelination as a risk factor for gliomagenesis, and highlight important considerations for the concurrent management of glioma and MS.”
BackgroundInfluentialEditorial: Spatiotemporal heterogeneity in CNS tumors
Faisal, S. M., Ravi, V. M., & Miska, J. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1430227 · Cited by 3
Locoregional Infusion of IL13Rα2-specific Immunotoxins in Children and Adults With high-grade Glioma
Rechberger, J. S., & Daniels, D. J. (2022) · Therapeutic Delivery · doi:10.4155/tde-2022-0019 · Cited by 2
Park, J. H., Lee, S., & Han, Y. T. (2024) · Tetrahedron Letters · doi:10.1016/j.tetlet.2024.155338 · Cited by 2
Prognostic signature detects homologous recombination deficient in glioblastoma
Luo, D., Luo, A., Hu, S., Zhao, H., Yao, X., Li, D., & Peng, B. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2077 · Cited by 2
“However, the overall survival rate of GBM is substantially below our expectations, and the 5-year survival rate is below 10% (2).”
Huang, M., Kang, Z., Li, S., Zhang, B., Xiao, Y., Li, S., & Li, W. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101141 · Cited by 2
“[3, 4].”
Pham, J. D., Sisti, J., Coté, D. J., Kang, K. M., Briggs, R. G., Gómez, D., Shah, I., Lawler, S. E., Chen, C. C., Attenello, F. J., et al. (2025) · Journal of neurosurgery · doi:10.3171/2025.1.jns242671 · Cited by 2
Liu, T., Liu, L., Gao, D., Li, W., Wu, X., Li, S., Zhang, B., Liu, Y., Shan, Q., Lou, M., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.164171 · Cited by 3
Treatment response assessment in glioblastoma with GRASP DCE-MRI
Vankan, B., Var, V., Rommers, N., Psychogios, M., & Todea, R. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112234 · Cited by 2
Factors associated with poor prognosis in elderly biopsy-only glioblastoma patients
Edriss, J., Cheung, J., Kronvall, E., Redebrandt, H. N., & Uvelius, E. (2025) · Acta Neurochirurgica · doi:10.1007/s00701-025-06681-7 · Cited by 2
“Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with a median overall survival (OS) of 15 months and a 5-year survival rate of only 5% [6, 34, 47].”
Bar-Letkiewicz, I., Pieczyńska, A., Dudzic, M., Szkudlarek, M., Adamska, K., & Hojan, K. (2025) · Biomedicines · doi:10.3390/biomedicines13112597 · Cited by 2
Stadlbauer, A., Nikolic, K., Marhold, F., Doerfler, A., Kinfe, T. M., Meyer‐Baese, A., Schnell, O., Ökrösi, A., Heinz‐Peer, G., & Oberndorfer, S. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8922 · Cited by 2
Chen, Z., Yang, Q., Fan, M., Chai, T., Liu, Y., Xia, X., Ismail, M., & Zheng, M. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123902 · Cited by 4
Parvez, A., Rahman, M. A., Shimki, A. I., Biswas, P., Hasan, M. H., Imtiaz, M., Sultana, A., Islam, S., Faraque, A., Amin, M. F., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501413 · Cited by 4
Rezk, A. M., Al-Fakih, A., Shazly, A., Singh, V. K., Roh, Y. H., Ryu, K., & Al‐masni, M. A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111387 · Cited by 2
Microfluidic biosensors and devices for brain tumor diagnosis and monitoring
Allela, O. Q. B., Alkhazali, W. H., Arora, V., Prahlad, P., Mohanty, B., Dhyani, A., Uppal, S., Aliev, M. A., Sameer, H. N., Yaseen, A., et al. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120796 · Cited by 2
Hahnfeldt, R., Laukamp, K. R., Schönfeld, M. H., Galldiks, N., Werner, J.-M., Fervers, P., Görtz, L., Gertz, R. J., Nelles, C., Nasirov, N., et al. (2025) · European Journal of Radiology Artificial Intelligence · doi:10.1016/j.ejrai.2025.100054 · Cited by 2
Electrophysiology of gliomas: current science, implications, and opportunities
Minns, H. E., Useinovic, N., Smith, J. L., Puri, S., Raslan, A. M., Paulk, A. C., & Cleary, D. R. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1611840 · Cited by 2
Ding, Y., Zhan, Q., Cui, L., Cui, X., Zhao, Y., Wang, Q., Hong, B., Huang, Y., Su, D., Cheng, C., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf293 · Cited by 3
Guo, M., Luo, W., Ling, P., Lei, H., Li, L., Duan, C., Xue, Z., Zhang, M., Zhang, X., Bao, W., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67418-9 · Cited by 2
Zhang, J., Wang, D., Liu, G., Bu, C., Lv, G., Li, M., Wei, S., Zhang, Z., Gao, Y., Yan, Z., et al. (2026) · Cancer · doi:10.1002/cncr.70253 · Cited by 2
Zhang, S., An, K., Lan, S., Chen, J., Yang, S., Li, C., Du, Y., Liu, B., Ke, P. C., Zhang, P., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100373 · Cited by 2
TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma
Asad, M., Inocencio, J. F., Mitrasinovic, S., Aoki, M., Baker, C. E., Hormigo, A., Crisman, C., LASALA, P. A., Eskandar, E. N., Guha, C., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag044 · Cited by 2
Figg, J., Love, C., Stansbury, S. M., Jin, D., Francis, C. P., Dean, B. D., Reid, A., Engelbart, M. K., West, I., Font, L. F., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag054 · Cited by 2
Wekalao, J., Elsayed, H. A., Alqhtani, H. A., Almawgani, A. H. M., Gumaih, H. S., Adam, Y. S., Mehaney, A., & Ochen, W. (2026) · AIP Advances · doi:10.1063/5.0305214 · Cited by 2
Han, L., Wang, Z., Jiang, Y., Zhou, H., & Zhou, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775148 · Cited by 5
Hu, Y., Nong, S., Zeng, Z., Tan, Y., Fang, X., Zhong, W., Wang, Z., Sui, X., Zhang, H., Liu, Q., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114990 · Cited by 2
Metadata
- Authors
- Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., Cloughesy, T. F., DeGroot, J. F., Galanis, E., Gilbert, M. R., Hegi, M. E., Horbinski, C., Huang, R. Y., Lassman, A. B., Le Rhun, E., Lim, M., Mehta, M. P., Mellinghoff, I. K., Minniti, G., Nathanson, D., Platten, M., Preusser, M., Roth, P., Sanson, M., Schiff, D., Short, S. C., Taphoorn, M. J. B., Tonn, J.-C., Tsang, J., Verhaak, R. G. W., von Deimling, A., Wick, W., Zadeh, G., Reardon, D. A., Aldape, K. D., & van den Bent, M. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Zurich (CH)
- Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio, USA
- The Jackson Laboratory for Genomic Medicine (US)
- Yale University (US)
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic (US)
- National Institutes of Health (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Northwestern University (US)
- NewYork–Presbyterian Hospital (US)
- University of Lille, Inserm, Neuro-oncology, General and Stereotaxic Neurosurgery service, University Hospital of Lille, Lille, France; Breast Cancer Department, Oscar Lambret Center, Lille, France and Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland
- Johns Hopkins University (US)
- Miami Cancer Institute, Miami, Florida, USA
- Memorial Sloan Kettering Cancer Center (US)
- University of Siena (IT)
- Heidelberg University (DE)
- Medical University of Vienna (AT)
- Centre National de la Recherche Scientifique (FR)
- University of Virginia (US)
- University of Leeds (GB)
- Leiden University Medical Center (NL)
- LMU Klinikum (DE)
- Neuropathology and Clinical Cooperation Unit Neuropathology, University Heidelberg and German Cancer Center, Heidelberg, Germany
- Princess Margaret Cancer Centre (CA)
- National Cancer Institute (US)
- Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Corresponding author
- Wen, Patrick Y
- Weller, Michael
- ORCID
- Wen, Patrick Y
- Weller, Michael
- Lee, Eudocia Quant
- Alexander, Brian M
- Barthel, Floris P
- Batchelor, Tracy T
- Bindra, Ranjit S
- Chang, Susan M
- Chiocca, E Antonio
- Cloughesy, Timothy F
- Galanis, Evanthia
- Gilbert, Mark R
- Hegi, Monika E
- Horbinski, Craig
- Huang, Raymond Y
- Lassman, Andrew B
- Lim, Michael
- Mehta, Minesh P
- Mellinghoff, Ingo K
- Minniti, Giuseppe
- Nathanson, David
- Platten, Michael
- Preusser, Matthias
- Roth, Patrick
- Sanson, Marc
- Schiff, David
- Short, Susan C
- Taphoorn, Martin J B
- Tonn, Joerg-Christian
- Tsang, Jonathan
- Verhaak, Roel G W
- Wick, Wolfgang
- Zadeh, Gelareh
- Reardon, David A
- Aldape, Kenneth D
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-24
- Volume
- 22
- Issue
- 8
- Pages
- 1073-1113
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC7594557
- OpenAlex
- W3020099303
- Cited by
- 1,168
- References
- 334
- Citations by year
- 2026: 166 · 2025: 215 · 2024: 242 · 2023: 204 · 2022: 194 · 2021: 118 · 2020: 28
- FWCI
- 71.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- IRIS (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- JuSER (Forschungszentrum Jülich) (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Funders
- University of Leeds
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (P01CA069246, P30CA008748, P50CA211015, P30CA016672, P01CA163205)
- National Institute of Neurological Disorders and Stroke (R35NS105109)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- glioblastoma, IDH-wildtype glioblastoma, adult brain tumors, molecular pathogenesis, targeted therapy, DNA damage response, metabolic therapy, immunotherapy, viral therapy, treatment management
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Isocitrate Dehydrogenase, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Chemoradiotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
